ROSGQ (Rosetta Genomics) Debt-to-Asset : 0.40 (As of Jun. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rosetta Genomics Debt-to-Asset?

Rosetta Genomics ROSGQ Debt-to-Asset is 0.40 as of Jun. 2017.

Rosetta Genomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2017 was $0.06 Mil. Rosetta Genomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2017 was $2.39 Mil. Rosetta Genomics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2017 was $6.21 Mil. Rosetta Genomics's debt to asset for the quarter that ended in Jun. 2017 was 0.39.

Rosetta Genomics  (OTCPK:ROSGQ) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Rosetta Genomics Debt-to-Asset Related Terms

Rosetta Genomics Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics Debt-to-Asset Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.32

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.01 0.32 0.40

ROSGQ vs TEAR, IDTA, ABMC: Debt-to-Asset Comparison

For the Diagnostics & Research subindustry, Rosetta Genomics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rosetta Genomics Debt-to-Asset vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Debt-to-Asset falls into.


Rosetta Genomics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Rosetta Genomics's Debt-to-Asset for the fiscal year that ended in Dec. 2016 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.055 + 3.74) / 11.961
=0.32

Rosetta Genomics's Debt-to-Asset for the quarter that ended in Jun. 2017 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.055 + 2.394) / 6.207
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.40 mean?
Rosetta Genomics (ROSGQ) has a Debt-to-Asset of 0.40 as of Jun. 2017. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' Debt-to-Asset too high?
Rosetta Genomics' current Debt-to-Asset is 0.40.
How does Rosetta Genomics' Debt-to-Asset compare to TEAR and IDTA?
Rosetta Genomics' Debt-to-Asset of 0.40 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Medical Diagnostics & Research company?
A good Debt-to-Asset depends on the Medical Diagnostics & Research industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Rosetta Genomics and its competitors. Rosetta Genomics's current Debt-to-Asset is 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Debt-to-Asset of 0.40. The current Debt-to-Asset is 0.40. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Debt-to-Asset is 0.40 as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.